|
|
|
|
Targeted Protein Degraders (TPDs) are redefining modern drug discovery and development. CDMOs play a critical role in this by offering infrastructure and analytics to support the transition from preclinical research to clinical supply and commercialization.
|
|
|
|
|
Anshul Gupte Ph.D., RAC Drugs, VP of Pharmaceutical Development, shares insight about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
|
|
|
|
|
Approximately 41% of drug compounds are highly potent, requiring advanced containment and robust technical transfer protocols. Learn how to overcome complex challenges through meticulous testing, specialized tooling, and strong supplier relationships.
|
|
|
|
|
Today's challenge isn't determining if targeted protein degraders work, but how to deliver these often bulky, poorly soluble molecules in a form the body can absorb. See how advanced enabling technologies have been the key to formulating these molecules.
|
|
|
|
|
Contrasting small-molecule inhibitors that block protein function, TPDs harness the body’s natural degradation systems to eliminate harmful proteins. This approach paves the way for novel therapies in oncology, neurodegenerative diseases, and immune-related conditions.
|
|
|
